407 related articles for article (PubMed ID: 26308285)
1. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.
Andersen R; Donia M; Westergaard MC; Pedersen M; Hansen M; Svane IM
Hum Vaccin Immunother; 2015; 11(12):2790-5. PubMed ID: 26308285
[TBL] [Abstract][Full Text] [Related]
2. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
Svane IM; Verdegaal EM
Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
[TBL] [Abstract][Full Text] [Related]
3. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
4. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
5. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
[TBL] [Abstract][Full Text] [Related]
8. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
Mayor P; Starbuck K; Zsiros E
Gynecol Oncol; 2018 Aug; 150(2):361-369. PubMed ID: 29803316
[TBL] [Abstract][Full Text] [Related]
9. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
[TBL] [Abstract][Full Text] [Related]
10. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
11. Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations.
Whiteside TL
In Vivo; 1991; 5(6):553-9. PubMed ID: 1810438
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
[TBL] [Abstract][Full Text] [Related]
13. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
Mallmann P; Krebs D
Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
[TBL] [Abstract][Full Text] [Related]
15. Adoptive T-cell transfer in melanoma.
Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
[TBL] [Abstract][Full Text] [Related]
16. [Application of gene therapy in tumor adoptive immunotherapy].
Wang C; Zhao Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
[TBL] [Abstract][Full Text] [Related]
17. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
18. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.
Sim GC; Chacon J; Haymaker C; Ritthipichai K; Singh M; Hwu P; Radvanyi L
BioDrugs; 2014 Oct; 28(5):421-37. PubMed ID: 24890028
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]